On October 28, Professor Gou Maling and her delegation from West China Hospital of Sichuan University and the National Key Laboratory of Biotherapy visited Sichuan Funengyuan Biotechnology Co., Ltd. Deng Jingen, Chief Scientist of R&D at Good Doctor Group; Geng Yuechang, Chairman of Funengyuan; and Li Nan, President of Funengyuan, together with the product team, gave them a warm reception. The two sides conducted in-depth and pragmatic exchanges and discussions centering on cutting-edge biotechnology and new quality productive forces in the pharmaceutical field. 01 On-Site Visit and Experience Professor Gou Maling and her delegation visited the "Good Doctor · Funengyuan" Brand Exhibition Hall and the Good Doctor Guzheng Traditional Chinese Medicine Clinic on site. They systematically learned about Funengyuan""s series of health products and its corporate culture of deeply cultivating "Herbal + Technology," gaining an intuitive understanding of Funengyuan""s industry-university-research ecosystem, which relies on Good Doctor Group and focuses on the general health industry. While visiting the Good Doctor Guzheng Traditional Chinese Medicine Clinic, Professor Gou Maling and her delegation gained an in-depth understanding of its operating model and personally experienced AI intelligent devices such as the intelligent tongue diagnosis device and the InBody physique identification device. They fully affirmed Funengyuan""s practice of using the traditional Chinese medicine clinic as a carrier to promote the downward extension of "Herbal + Technology" health services. 02 Introduction to Core Scientific Research Achievements During the discussion and exchange, Professor Gou Maling introduced the general situation of the National Key Laboratory of Biotherapy. Relying on the National Major Science and Technology Infrastructure for Translational Medicine, the laboratory has a research team of 2,000 people and adheres to a multidisciplinary and translational medicine orientation. Its projects take into account both clinical value and business logic, and multiple technologies have already incubated companies and carried out clinical trials. Focusing on research directions and achievements, Professor Gou Maling introduced areas such as biological 3D printing, the microneedle technology system, and gene and cell therapy, and briefly introduced the relevant pipeline of products under development, reflecting the laboratory""s layout in translational medicine and industrialization. 03 Discussing Future Cooperation Space During the exchange, Deng Jingen introduced Good Doctor Group""s layout in raw material assurance for general health and pharmaceutical research directions. Combining Funengyuan""s practices in herbal technology and the general health industry, he conducted in-depth discussions with Professor Gou Maling on the industrial transformation paths of cutting-edge biotechnology, safety evaluation, and product development logic. Both sides believe that the scientific research team""s technological accumulation and Funengyuan""s industrial resources are highly complementary, and that cooperation space can be explored in areas such as health product R&D and the transformation of technological achievements. This exchange laid a solid foundation for the two sides to deepen industry-university-research cooperation. In the future, both sides will fully leverage the technological advantages of research institutes and the industrialization advantages of enterprises, jointly explore development paths for new quality productive forces in the pharmaceutical field, and contribute greater strength to the building of a Healthy China.